相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Molecular Characterization of Extended-Spectrum-β-Lactamase-Producing and Plasmid-Mediated AmpC β-Lactamase-Producing Escherichia coli Isolated from Stray Dogs in South Korea
Migma Dorji Tamang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Decreased Susceptibility to Noncarbapenem Antimicrobials in Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates in Toronto, Canada
Christopher F. Lowe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette Chromosome mec Types
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Clinical and Microbiologic Characteristics of Cephalosporin-Resistant Escherichia coli at Three Centers in the United States
Yoon Soo Park et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program
Robert K. Flamm et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Combination of Doripenem and Colistin Is Bactericidal and Synergistic against Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae
Meredith G. Jernigan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Molecular Epidemiological Analysis of Escherichia coli Sequence Type ST131 (O25:H4) and blaCTX-M-15 among Extended-Spectrum-β- Lactamase-Producing E. coli from the United States, 2000 to 2009
James R. Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Diverse Sequence Types of Klebsiella pneumoniae Contribute to the Dissemination of blaNDM-1 in India, Sweden, and the United Kingdom
Christian G. Giske et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Wild Coastline Birds as Reservoirs of Broad-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Miami Beach, Florida
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria
Elizabeth B. Hirsch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Antimicrobial Resistance of Urinary Escherichia coli Isolates among US Outpatients from 2000 to 2010
Guillermo V. Sanchez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Progress on Developing Endpoints for Registrational Clinical Trials of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections: Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health
George H. Talbot et al.
CLINICAL INFECTIOUS DISEASES (2012)
Identification of CTX-M β-lactamases among Escherichia coli from the community in New York City
Hemavarna Tiruvury et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone
Todd A. Davies et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum -lactamase-producing Escherichia coli
Niki Lampri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
200 NEJM ANNIVERSARY ARTICLE The Perpetual Challenge of Infectious Diseases
Anthony S. Fauci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CTX-M enzymes: origin and diffusion
Rafael Canton et al.
FRONTIERS IN MICROBIOLOGY (2012)
Molecular Characterization of Resistance to Extended-Spectrum Cephalosporins in Clinical Escherichia coli Isolates from Companion Animals in the United States
Bashar W. Shaheen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro and In Vivo Properties of BAL30376, a β-Lactam and Dual β-Lactamase Inhibitor Combination with Enhanced Activity against Gram-Negative Bacilli That Express Multiple β-Lactamases
Malcolm G. P. Page et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
New antimicrobial agents on the horizon
Karen Bush et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Will new antimicrobials overcome resistance among Gram-negatives?
Matteo Bassetti et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2011)
Antimicrobial Stewardship
Pranita D. Tamma et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2011)
Antibiotics in the clinical pipeline in 2011
Mark S. Butler et al.
JOURNAL OF ANTIBIOTICS (2011)
Metallo-β-lactamases: a last frontier for β-lactams?
Giuseppe Cornaglia et al.
LANCET INFECTIOUS DISEASES (2011)
Ceftriaxone-Resistant Neisseria gonorrhoeae, Japan
Makoto Ohnishi et al.
EMERGING INFECTIOUS DISEASES (2011)
Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains
Carlos Juan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
David N. Gilbert et al.
CLINICAL INFECTIOUS DISEASES (2010)
Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin-Structure Infection
G. Ralph Corey et al.
CLINICAL INFECTIOUS DISEASES (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae
Karen Bush
CURRENT OPINION IN MICROBIOLOGY (2010)
Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria
Ann Pallett et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy et al.
LANCET INFECTIOUS DISEASES (2010)
CURRENT CONCEPTS Hospital-Acquired Infections Due to Gram-Negative Bacteria
Anton Y. Peleg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Current and novel antibiotics against resistant Gram-positive bacteria
Federico Perez
Infection and Drug Resistance (2010)
Emergence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout North Carolina: A Harbinger of a Wider Problem in the United States?
Joshua T. Freeman et al.
CLINICAL INFECTIOUS DISEASES (2009)
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2009)
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates
David M. Livermore et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Has the era of untreatable infections arrived?
David M. Livermore
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Antibiotic-Resistant Bugs in the 21st Century -- A Clinical Super-Challenge.
Cesar A. Arias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections
Gary J. Noel et al.
CLINICAL INFECTIOUS DISEASES (2008)
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007
Alicia I. Hidron et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2008)
Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern
Johann D. D. Pitout et al.
LANCET INFECTIOUS DISEASES (2008)
First report of the emergence of CTX-M-Type extended-spectrum β-lactamases (ES-BLs) as the predominant ESBL isolated in a US health care Systemdel
James S. Lewis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus
M. E. Jones
CLINICAL MICROBIOLOGY AND INFECTION (2007)
Bacteremia due to extended-spectrum β-lactamase producing Escherichia coli in the CTX-M era:: A new clinical challenge
Jesus Rodriguez-Bano et al.
CLINICAL INFECTIOUS DISEASES (2006)
The CTX-M β-lactamase pandemic
Rafael Canton et al.
CURRENT OPINION IN MICROBIOLOGY (2006)
The future should not look like the past
[Anonymous]
LANCET INFECTIOUS DISEASES (2006)
Emerging metallo-β-lactamase-mediated resistances:: A summary report from the worldwide SENTRY Antimicrobial Surveillance Program
TR Fritsche et al.
CLINICAL INFECTIOUS DISEASES (2005)
Mechanisms of disease:: The new β-lactamases
GA Jacoby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
